02459nas a2200253   4500000000100000008004100001653001200042653001300054653002200067653001200089653001500101100001500116700001500131700001500146700001100161700001400172700001200186700001500198245014400213856007100357300001000428490000700438520176000445       2017                            d10aleprosy10aPost RFT10aDeleterious event10aRelapse10aestimation1 aShetty V P1 aPandya S S1 aKamble S M1 aShah S1 aDighe A R1 aPai V V1 aThakar U H00aEstimation of deleterious events in 577 leprosy patients released from treatment between 2005-2010 in urban and rural areas of Maharashtra.  uhttp://www.ijl.org.in/2017/3%20VP%20shetty%20et%20al%20(77-90).pdf  a77-900 v893 a<p>This is a study of deleterious events in leprosy patients released from treatment (RFT) between 2005-2010, in 3 municipal health posts in Mumbai (SA1 urban) and 5 primary health centres (Gavan, Apta, Nere, Wavanje and Ajivali) in Panvel Taluka (SA2 Rural) of Raigad district of Maharashtra. There were a total of 1162 registered RFT patients including 542 in SA1 and 620 in SA2 of which a total of 577 including 350 MB and 227 PB patients were successfully traced and examined in 3 annual home visits between 2012-2014. Remaining 588 (51%) were either lost to follow-up or non-consenting. The sampling conditions for both SA1 and SA2 in the context of markers such as MB : PB ratio, were found to be satisfactory. Total of 104 (18%) cases were detected with deleterious events. Five were children (4.8%). Females out-numbered males (M: F=0.8:1). The proportions were similar in SA1 (16%) and SA2 (19%). It was higher in MB (SA1=20%, SA2=15%) as compared to PB patients (SA1=11.7, SA2=8.3%). Neuritis was the most common event (64 patients), followed by relapse (54 patients), the majority being BT-BB treated with 12 months MB-MDT. Other events were, persistence of skin lesion in 31, silently progressing neuropathy in 13, lepra reaction in 21 cases. Simultaneous deleterious events were seen in 60, recurrent neuritis/reaction in 27, and worsening nerve function impairment (NFI) in 52 patients. While rates/frequencies of different deleterious events may not be truly representative of magnitude of these problems in this patient population due to significant loss to follow-up and different durations of follow up, these figures highlight the need for a vigorous Post-RFT surveillance, timely and appropriate management of deleterious events.</p>